drugset / Trial / NCT07392541

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

NCT07392541

Phase 1/2 Recruiting 29 enrolled Tongji Hospital
NaSingle-groupOpen-labelTreatment

Summary

This study will investigate the safety and effectiveness of a new combination treatment for patients with advanced bile duct cancer. The treatment combines standard chemotherapy drugs (gemcitabine and cisplatin) with two additional medications: adebrelimab and simvastatin. All participants in this study will receive the same four-drug combination. Researchers will closely monitor patients to see how well the tumors shrink, how long the treatment keeps the cancer from growing, and what side effects occur. The study is exploratory, meaning it aims to gather initial data on whether this four-drug combination is a promising approach for treating advanced biliary tract cancer.

Timeline

Start
2026-01-30
Primary completion
2028-01-30
Completion
2028-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Adebrelimab Monoclonal antibody 1200 mg Intravenous
Subject Simvastatin Small molecule 20 mg Oral
Background Cisplatin Other / unclassified Intravenous
Background Gemcitabine Small molecule Intravenous

Indications